Pricing
  1. US-listed companies
  2. Emergent BioSolutions Inc.
  3. Financials
  4. Long-term debt, non-current

Emergent BioSolutions Inc. (EBS)

Market cap
$446.71M
P/E ratio
SummaryFinancials
Period EndLong-term debt, non-current (Million USD)YoY (%)
Dec 31, 2024664+48.65%
Dec 31, 2023447-0.45%
Dec 31, 2022449-44.59%
Dec 31, 2021809-3.76%
Dec 31, 2020841+5.34%
Dec 31, 2019798+1.77%
Dec 31, 2018785+5729.68%
Dec 31, 201713-94.58%
Dec 31, 2016248-1.94%
Dec 31, 2015253+308.06%
Dec 31, 201362+6.34%
Dec 31, 201258+7.78%
Dec 31, 201154

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat